Press Release

20

2019-09

InxMed Receives US FDA IND Approval to Initiate Clinical Trial for IN10018

Shanghai, China—InxMed (Shanghai) Co., Ltd. (“InxMed” or “Company”), announced that the Company has obtained FDA (Food and Drug Administration) IND clearance for IN10018, a proprietary focal adhesion kinase (FAK) inhibitor. This is InxMed's first IND opening approved by FDA, which reflects the company's superior R&D capability.

< 12345 > proceed page
图片名称

QUICK LINKS

CONTACT US

Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

MESSAGE

%{tishi_zhanwei}%

CopyRight © 2026 InxMed All Rights Reserved.

SEO

Powered by：CEglobal